Vaxil Bio Ltd (VXLLF)

[deadjim]

VXLLF otc vaccine maker -- marked

axil Announces Collaboration Agreement With The Tel Aviv Sourasky Medical Center (Ichilov Hospital), Israel’s Leading Tertiary Care Facility
Not for distribution by US newswire or in United States
NESS-ZIONA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce the signing of a collaboration agreement between the Company and The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center (the “Tel Aviv Medical Center”) to advance the Company’s research program to develop a potential peptide vaccine against COVID-19.

This agreement provides Vaxil with vital access to Tel Aviv Medical Center’s research resources including their unique bank of biological samples and its advanced research infrastructure. Dr. David Hagin, Director of the Allergy and Clinical Immunology Unit, will progress our pre-clinical work and clinical trials.

“This collaboration agreement is an central milestone in the pre-clinical stage of our COVID-19 vaccine candidate research, and provides a clear pathway to potential clinical trials during 2020”, said David Goren, Vaxil’s Chairman and Chief Executive Officer. He continued to say “the The Aviv Medical Center is a leading hospital and is at the forefront of fighting the COVID-19 pandemic in Israel. We look forward to working with Dr. Hagin and their world-class medical and research teams on this program.”

Dr. Hagin added “Use of the signal peptide platform, which targets infected cells rather than the virus is unique and exciting. I see great potential in this innovative approach to develop a potential COVID-19 vaccine. We share Vaxil’s vision of creating a vaccine quickly for the benefit of people all over the world.”

The Company does not anticipate the need to raise additional funds to finance this work.

The Company is not making any express or implied claims that it has completed developing or will be successful in developing a vaccine to treat COVID-19 (or SARS-CoV-2) at this time.